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Abstract
Purpose Cardiovascular diseases (CVDs) are a leading cause of morbidity and mortality worldwide, necessitating major efforts
in prevention. This review summarizes the currently available training opportunities in CVD prevention for fellows-in-training
(FITs) and residents. We also highlight the challenges and future directions for CVD prevention as a field and propose a structure
for an inclusive CVD prevention training program.
Recent Findings At present, there is a lack of centralized training resources for FITs and residents interested in pursuing a career
in CVD prevention. Training in CVD prevention is not an accredited subspecialty fellowship by the American Council of
Graduate Medical Education (ACGME). Although there are several independent training programs under the broad umbrella
of CVD prevention focusing on different aspects of prevention, there is no unified curriculum or training.
Summary More collaborative efforts are needed to identify CVD prevention as an ACGME-accredited subspecialty fellowship.
Providing more resources can encourage and produce more leaders in this essential field.
Keywords Heart disease prevention . CVD prevention training . Cardiology training programs . Preventive cardiology training .
Fellowship . Fellows-in-training
Introduction
Approximately 2200 Americans die from cardiovascular dis-
ease (CVD)-related causes each day, an average of 1 death
every 40 s [1]. According to the 2017 heart disease and stroke
statistics update by the American Heart Association (AHA),
about 92.1 million American adults are living with some form
of CVD including coronary heart diseases (CHDs) or strokes.
There is also an alarming increase in the incidence of CHD
among younger adults [1]. The annual direct and indirect costs
from CHD and stroke is estimated to total more than $316
billion when including both health expenditures and lost
productivity.
There is robust evidence that CVD is a potentially modifi-
able disease. Although atherosclerosis is a life-long process,
risk factor modification helps with the prevention of CVD
events and associated morbidities. Additionally, with the
ever-growing need for cost-efficient delivery of care and in-
troduction of quality payment programs, most notably the
Medicare and CHIP Reauthorization (MACRA) Act 2015,
the focus has shifted to high-quality care at a low cost.
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Preventive strategies have been shown to have the lowest cost
per quality-adjusted life-years [2].
Data also suggest that many patients who are at high
risk of CVD or those with established coronary diseases or
strokes remain unidentified and/or inadequately treated
[3]. Pokharel et al. have previously shown suboptimal
statin use and facility-level variation in statin prescriptions
for patients at high risk for CHD [3]. Results from the
PINNACLE (Pract ice INNovation And CLinical
Excellence) registry, a national cardiology outpatient qual-
ity improvement registry which extracts data from elec-
tronic medical records, revealed that approximately 38%
of patients with diabetes in cardiology practices had no
documentation of a statin prescription [4]. We know that
individuals with familial hypercholesterolemia (FH), if un-
treated, are at least 20 times more likely to have incident
CHD events than those without FH [5]. Early cross-
sectional data from the national FH registry (CASCADE-
FH) showed that the median age of diagnosis for adults
with FH in the USA was 47 years [3]. Currently, not only
are individuals with FH likely to be diagnosed very late in
life but also under-treated, with only 25% patients in the
CASCADE-FH registry reaching low-density lipoprotein
cholesterol levels < 100 mg/dL [3]. A recent study showed
subclinical atherosclerosis can be detected by ultrasonog-
raphy and coronary calcium tests in a cohort of middle-
aged individuals without traditional risk factors for CVD
[6]; highlighting the potential need for early risk stratifi-
cation [7]. Education in CVD prevention including famil-
iarity and use of newer diagnostic modalities are key to a
more comprehensive detection of high-risk CVD popula-
tions. Newer biomarkers such as high-sensitivity troponin
T and N-terminal pro brain natriuretic peptide (NT-
proBNP) measured by very sensitive assays can diagnose
subclinical myocardial injury, and these biomarkers have
been shown to improve risk prediction of coronary heart
diseases and heart failure. Use of coronary artery calcium
scoring has been established as a diagnostic marker for
subclinical atherosclerosis. Thus, a number of diagnostic
modalities have a potential to be highly useful in clinical
practices for CVD prevention.
Cardiologists and primary care providers have a crucial
role to play in prevention of CVD events; by first and fore-
most, identifying high-risk individuals, then applying life-
style interventions and pharmacotherapies, and coordinat-
ing multidisciplinary care, including cardiac rehabilitation,
when indicated. However, most of the experience in this
field comes “on the fly” while training. Currently, there is
a lack of strategically designed subspecialty training in
CVD prevention. Further, there is an absence of consensus
on the necessary curriculum for training programs as well
as a lack of a centralized resources for CVD prevention
training programs [8••].
In this article, we review available resources for CVD pre-
vention training. Further, we highlight the leading challenges
for training in this niche area of CVD prevention.
Status of Cardiovascular Disease Prevention Training
in the USA
Over the last two decades, there has been incremental growth
in our understanding of CVD risk factors. Hence, there has
been a rapid influx of newer guidelines related to lipids, hy-
pertension, diabetes mellitus, obesity, thrombosis, and vascu-
lar diseases. As a result, various independently funded fellow-
ships have emerged with a focus on these specific disciplines,
aimed at providing advanced training.
In 2012, a survey of the US cardiology fellowship training
programs revealed that only 24% of the surveyed programs
met the Core Cardiovascular Training Symposium
(COCATS) guidelines with a dedicated 1-month rotation in
preventive cardiology (used interchangeably with CVD pre-
vention). Approximately, 24% of the programs had no formal-
ized training in CVD prevention and 30% had no faculty with
expertise in the field [9]. “Lack of time” and “lack of a devel-
oped curriculum in prevention” were cited as the most prom-
inent barriers to training in CVD prevention by program di-
rectors and chief fellows of the surveyed programs [9].
Following this survey, the COCATS 4 Task Force 2 guide-
lines were published in 2015 and endorsed by the American
board of Internal Medicine (ABIM) and Accreditation
Council of Graduate Medical Education (ACGME) [3]. This
document recognized primary and secondary atherosclerotic
CVD prevention strategies as core learning principles during
general cardiology fellowship training. As with most other
adult CVD areas, three levels of training were described and
are currently applicable [10••], as follows:
& Level 1: Basic training required for all physicians to be-
come competent cardiologists. This level of training can
be achieved by at least 1 month of training dedicated to
CVD prevention medicine. This 1-month rotation should
encompass weekly attendance at a cardiac rehabilitation
program, diabetes or endocrinology clinic, hypertension
clinic, and dyslipidemia management clinic.
An alternative to the 1 month dedicated to CVD prevention
is a 3-month (or longer) training in comprehensive cardiac
rehabilitation with at least weekly attendance.
& Level 2: Additional training in “1 or more areas that en-
able cardiologists to perform or interpret specific proce-
dures or render more specialized care for specific patients
and conditions.” For prevention, the Task Force identified
no specific competencies for Level II training.
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& Level 3: For trainees who are interested in seeking exper-
tise to attain program director-level positions in clinical,
research or combined programs. No formal level III train-
ing program or curriculum has been identified for CVD
prevention as of yet. Trainees are encouraged to attain
additional (currently non ACGME-accredited) fellow-
ships to achieve level III.
The core competencies in CVD prevention modules (grad-
ed by milestones) for trainees were also delineated by the
COCATS 4 Task Force guidelines which included six do-
mains (medical knowledge, patient care and procedural skills,
system-based practice, practice-based learning and improve-
ment, professionalism and interpersonal and communication
skills). Further, a strong emphasis was placed on learning risk
factor modification strategies in curtailing the progression of
subclinical atherosclerosis as well as CHD-associated morbid-
ity and mortality [10••].
As a result, general cardiology fellow in training (FITs) are
mandated to spend at least 1 month of their 36-month training
period in a prevention setting to obtain the minimum level of
expertise in CVD prevention and meet the aforementioned
milestones. Although COCATs level I preventive training is
required of all cardiology FITs [10••], trainees who are inter-
ested in pursuing a career in CVD prevention will likely re-
quire an additional 1–2 years of training.
Potential Challenges in CVD Prevention Training
The initial challenge in pursuing a career in CVD prevention is
the absence of centralized resources or consolidated catalog of
prospective training opportunities for fellows or residents.
Similarly, there is no central board/society which would allow
certification in preventive cardiology. Furthermore, candidates
who are on a visa may face additional difficulty as their visas
may not be acceptable for training at many of the programs.
Unlike the traditional medicine residencies or ABIM rec-
ognized subspecialty fellowships, CVD prevention fellow-
ships do not have an “Electronic Residency Application
Service” (ERAS) like application portal which streamlines
the application process, includes a list of all currently available
programs, and manages application submissions as well as
communication related to interview invitations.
Although several societies provide guidelines and recom-
mendations onmanagement of various aspects of CVD preven-
tion [11–13], there is currently a lack of a formalized curricu-
lum for CVD prevention fellowship training which has been
endorsed uniformly across all societies. Further, the duration of
a CVD prevention fellowship may vary from institution to
institution. Depending on the program, training may be 1 or
2 years and include research and/or clinical time to various
degrees. Most 2-year fellowships include a research year with
focuses including basic science, genetics, translational, and/or
outcomes/quality improvement. Given the growing need for
this subspecialty in the USA and worldwide, there have been
recent suggestions for ABIM accreditation of preventive cardi-
ology as a fifth subspecialty in cardiology [8••].
Current Programs and Available Certifications
Various training options are available for interested candidates
which may cover (but are not limited to) general topics in
CVD prevention as below:
& Lipid and hypertension management strategies for prima-
ry and secondary prevention
& Obesity management
& Cardiac rehabilitation
& Cardiovascular genomics
& Design and conduct of clinical trials
& Biostatistics and epidemiological training in CVD
Pack et al. previously published a consolidated list of 15
such training programs [14]. However, given that this was
published at least 5 years ago, changes in program websites,
application deadlines, and training descriptions are likely. We
have therefore outlined currently existing programs that we
are aware of in Table 1. All programs were contacted to ensure
ongoing training. Furthermore, current contact information is
provided in this updated table.
In addition to these independently funded opportunities in
CVD prevention training, there exists a comprehensive list of
the National Heart Lung and Blood Institute (NHLBI)-funded
Epidemiology and Statistical training programs for MDs and
PhDs interested in CVD prevention on its official website [15].
These programs, which are primarily research-oriented and
aimed towards training predoctoral and postdoctoral applicants,
are an important pathway towards becoming an investigator in
the field of CVD prevention. However, the NIH-funded pro-
grams are only open to US citizens or non-citizen nationals or
green card holders and those on temporary or student visas are
generally not eligible to apply for these positions.
We are not certain how many prospective applicants are
familiar with the NHLBI website resources. Therefore, we
have summarized some of these programs in Table 2. A com-
plete list of the NHLBI-funded training programs can also be
found at https://www.nhlbi.nih.gov/research/training/epi-bio.
Given that there is no ACGME accreditation for CVD pre-
vention, the programs are in general sponsored by the local
state medical board. The lack of ownership by a centralized
board for CVD prevention training is a major limiting factor in
formalized learning for this essential subspecialty.
Currently, the National Lipid Association independently con-
trols the American Board of Clinical Lipidology, which provides
a certification in lipidology which is not affiliated with or en-
dorsed by the ABIM. It also provides an annual Masters in
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Clinical Lipidology course for interested trainees and other
healthcare providers. Other societies which provide board certi-
fications or online continuing medical education (CME) oppor-
tunities include The American Society of Preventive Cardiology
(Online CME courses), American Society of Hypertension
(Specialist in Clinical Hypertension Certification and Certified
Hypertension Clinician Certificate), American Obesity Society
(American Board of Obesity Management Certification), and
American Association of Diabetes Educators (Board
Certification in Advanced Diabetes Management). More infor-
mation on these courses are detailed on the respective organiza-
tion’s official websites.
Directions for the Future
Prevention of CVD remains one of the major goals for the scien-
tific and healthcare community. Therefore, CVD prevention (both
primary and secondary) requires dedicated attention and training.
However, preventive cardiology is a subspecialty that is at times,
lost between clinical internal medicine, endocrinology, and cardio-
logy with no clear champion. Resources and formalized structure
in CVD prevention training are scant. Although the ACC
COCATSguidelines provide a general framework and recommen-
dations for basic training in CV prevention that is required of all
training programs in cardiovascular medicine, several programs
still lack the requirements for basic training in CVD prevention.
Moving forward, it is important for central educational
bodies like the ABIM to recognize CVD prevention as a
subspecialty of cardiovascular disease training. Leading pro-
fessional organizations like the American College of
Cardiology (ACC) and American Heart Association (AHA)
can collaborate with other organizations focused on CVD pre-
vention to provide resources and help develop CVD preven-
tion training programs. There are several ways ACC/AHA can
collaborate with the CVD training programs which include
(and may not be limited to) creating a central resource list
for training opportunities which is readily accessible for
trainees and providing resources to institutions with CVD fel-
lowship programs, such as offering online curriculum focused
on preventative training (lipid disorder management, smoking
cessation, resistant hypertension, and cardiac rehabilitation).
Potential Structure of Fellowship Training
Although the structure of currently available fellowships in
CVDprevention depends on the specific home institution,mov-
ing forward, an ACGME-approved curriculum will be benefi-
cial for comprehensive training. In our opinion, a fellowship
program for CVD prevention should aim to train both clinicians
and physician-scientists who will advance the field. Shapiro
et al. have recently suggested what preventive cardiology fel-
lowships should include (8). Table 3 illustrates our proposed
structure for a CVD prevention fellowship training program.
The clinician track may encompass a 1-year clinical training
where FITs train in lipid, diabetes, hypertension, obesity, and
cardiac rehabilitation which will aid them with the management
Table 3 Suggested cardiovascular
disease prevention training
program outline
Track Clinical Track Physician-Scientist Track
Duration (years) 1 1–2
Clinical Exposurea 3 or more half day clinics per week 1–2 half-day clinics per week
• Lipid clinic
• Hypertension
• Diabetes management
• Cardiac rehabilitation
• Dietician/lifestyle management
• Heart failureb Prevention
Adolescent preventive
medicine clinic
Research training Basic research methodology and
statistics understanding
> 1 publication per year Atleast 1 project/publication
in the year
Grant writing training
Additional; MPH/MSCR Course
Degree/CSTP Course
Conferences/Journal Club Weekly Weekly
CSTPClinician-Scientist Training Program,MPHMasters in Public Health,MSCRMasters in Science in Clinical
Research
a Clinical exposure includes multiple clinics including but not limited to the mentioned clinical training themes
bHeart Failure Prevention is, at present, not an established clinical model
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of complex cases referred by other specialists. For the physician-
scientist track, training will be geared towards producing re-
searchers in CVD prevention. The physician-scientist track
FITs would benefit from clinical exposure during the course of
their fellowship. However, more time would likely be allocated
to learning research methodology and grant writing skills.
In the future, another aspect of a CVD prevention fellow-
ship could be dedicated to primordial prevention in addition to
primary and secondary prevention. Collaboration between
adult and pediatric cardiologists could allow FITs to spend
time acquiring skills necessary for evaluation of children/teen-
agers/adolescents who are at high risk for developing CVD
and associated risk factors like diabetes and hypertension.
Conclusions
In today’s era, knowledge of the various aspects of CVD pre-
vention is becoming increasingly relevant. CVD prevention is
fundamental to global cardiovascular care, and there is room
for improvement in training cardiology FITs and other trainees
interested in this field. The central educational bodies should
take important further steps such as recognizing CVD preven-
tion as a subspecialty of cardiovascular medicine as well as
creating and endorsing a central portal for the training oppor-
tunities in this field. These measures can aid trainees in fur-
thering their clinical and research expertise in this area and
provide networking opportunities with faculty and other
trainees with a focus in CVD prevention. The ACC/AHA
can significantly help further this mission. It is our belief
and hope that implementation of such measures will encour-
age and prepare more leaders in the field of CVD prevention.
Compliance with Ethics Guidelines
Conflict of Interest Anum Saeed and Kaustubh Dabhadkar declare no
conflict of interest. Salim S. Virani receives an honorarium from the
American College of Cardiology as Associate Editor for Innovations for
ACC.org. Peter H. Jones has been a scientific consultant to Amgen and to
Sanofi/Regeneron the past 12 months. Vijay Nambi was on a regional
advisory board for Sanofi and is named on provisional patent no.
61721475 entitled “Biomarkers to Improve Prediction of Heart Failure
Risk” filed by Baylor College of Medicine and Roche. Christie M.
Ballantyne has received grant/research support (all paid to institution,
not individual) from Abbott Diagnostic, Amarin, Amgen, Eli Lilly,
Esperion, Ionis, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-
Synthelabo, NIH, AHA, and ADA; has been a consultant for Abbott
Diagnostics, Amarin, Amgen, Astra Zeneca, Boehringer Ingelheim, Eli
Lilly, Esperion, Ionis, Matinas BioPharma Inc., Merck, Novartis, Pfizer,
Regeneron, Roche Diagnostic, and Sanofi-Synthelabo; and is named on
provisional patent no. 61721475 entitled “Biomarkers to Improve
Prediction of Heart Failure Risk” filed by Baylor College of Medicine
and Roche.
Human and Animal Rights and Informed Consent This article does not
contain any studies with human or animal subjects performed by any of
the authors.
References
Papers of particular interest, published recently, have been
highlighted as:
•• Of major importance
1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R,
et al. Heart disease and stroke Statistics-2017 update: a report from
the American Heart Association. Circulation. 2017;135:e146–603.
2. Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save
money? Health economics and the presidential candidates. N Engl J
Med. 2008;358:661–3.
3. Nambi V, Liu X, Chambless LE, de Lemos JA, Virani SS, Agarwal
S, et al. Troponin Tand N-terminal pro-B-type natriuretic peptide: a
biomarker approach to predict heart failure risk—the atherosclero-
sis risk in communities study. Clin Chem. 2013;59:1802–10.
4. Pokharel Y, Gosch K, Nambi V, Chan PS, Kosiborod M, Oetgen
WJ, et al. Practice-level variation in statin use among patients with
diabetes: insights from the PINNACLE registry. J AmColl Cardiol.
2016;68:1368–9.
5. Onorato A, Sturm AC. Heterozygous familial hypercholesterol-
emia. Circulation. 2016;133:e587–9.
6. Fernandez-Friera L, Fuster V, Lopez-Melgar B, et al. Normal LDL-
cholesterol levels are associated with subclinical atherosclerosis in
the absence of risk factors. J Am Coll Cardiol. 2017;70:2979–91.
7. Nambi V, Bhatt DL. Primary prevention of atherosclerosis: time to
take a selfie? J Am Coll Cardiol. 2017;70:2992–4.
8.•• ShapiroMD, Fazio S. Setting the agenda for preventive cardiology.
Circ Res. 2017;121:211–3. A comprehensive paper which de-
scribed an potential preventive cardiology service for practical
purposes and preventive cardiology training outline.
9. PackQR, Keteyian SJ,McBride PE,WeaverWD,KimHE. Current
status of preventive cardiology training among United States cardi-
ology fellowships and comparison to training guidelines. Am J
Cardiol. 2012;110:124–8.
10.•• Smith SC Jr, Bittner V, Gaziano JM, et al. COCATS 4 task force 2:
training in preventive cardiovascular medicine. J Am Coll Cardiol.
2015;65:1754–62. An important document published by the
American College of Cardiology on the requirements for
trainees for achieving milestones in cardiovascular disease pre-
vention during their general cardiovascular disease fellowship
training.
11. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH,
et al. National lipid association recommendations for patient-
centered management of dyslipidemia: part 1—full report. J Clin
Lipidol. 2015;9:129–69.
12. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. ACC expert
consensus decision pathway on the role of non-statin therapies for
LDL-cholesterol lowering in the management of atherosclerotic
cardiovascular disease risk: a report of the American College of
Cardiology Task Force on clinical expert consensus documents. J
Am Coll Cardiol. 2016;68:92–125.
13. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT,
Fonseca VA, Garber AJ, et al. American Association of Clinical
Endocrinologists and American College of Endocrinology guide-
lines for management of dyslipidemia and prevention of cardiovas-
cular disease. Endocr Pract. 2017;23:1–87.
14. Pack QR, Keteyian SJ, McBride PE. Subspecialty training in pre-
ventive cardiology: the current status and discoverable fellowship
programs. Clin Cardiol. 2012;35:286–90.
15. NHLBI. National Heart Lung and blood institute, National
Research Service Award Programs in cardiovascular epidemiology,
biostatistics, and Prev Med 2017.
Curr Atheroscler Rep (2018) 20: 35 Page 7 of 7 35
